BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Lung cancer is the leading cause of cancer death in Korea as well as in other countries.
About 80% of lung cancer is non-small cell lung cancer(NSCLC). The majority of patients with
NSCLC require cytotoxic chemotherapy in the course of their illness. Combination chemotherapy
using third generation anticancer drugs (paclitaxel, docetaxel, gemcitabine) with
platinums(cisplatin or carboplatin) reached a plateau in their efficacy. Oxaliplatin, another
platinum being used for colorectal, gastric and pancreatic cancer has lower adverse effects
such as nausea and nephrotoxicity. In this phase II trial, we will observe efficacy and
safety of docetaxel and oxaliplatin for patients with NSCLC.